Pfizer Income Taxes 2010-2024 | PFE

Pfizer annual/quarterly income taxes history and growth rate from 2010 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.
  • Pfizer income taxes for the quarter ending September 30, 2024 were $0.234B, a 124.27% decline year-over-year.
  • Pfizer income taxes for the twelve months ending September 30, 2024 were $-0.402B, a 346.67% increase year-over-year.
  • Pfizer annual income taxes for 2023 were $-1.115B, a 133.5% decline from 2022.
  • Pfizer annual income taxes for 2022 were $3.328B, a 79.7% increase from 2021.
  • Pfizer annual income taxes for 2021 were $1.852B, a 400.54% increase from 2020.
Pfizer Annual Income Taxes
(Millions of US $)
2023 $-1,115
2022 $3,328
2021 $1,852
2020 $370
2019 $583
2018 $-266
2017 $-9,049
2016 $1,123
2015 $1,990
2014 $3,120
2013 $4,306
2012 $2,221
2011 $3,621
2010 $1,153
2009 $2,145
Pfizer Quarterly Income Taxes
(Millions of US $)
2024-09-30 $234
2024-06-30 $-134
2024-03-31 $293
2023-12-31 $-795
2023-09-30 $-964
2023-06-30 $-71
2023-03-31 $715
2022-12-31 $230
2022-09-30 $356
2022-06-30 $1,570
2022-03-31 $1,172
2021-12-31 $249
2021-09-30 $-328
2021-06-30 $1,123
2021-03-31 $808
2020-12-31 $-64
2020-09-30 $-347
2020-06-30 $422
2020-03-31 $359
2019-12-31 $-1,982
2019-09-30 $3,047
2019-06-30 $-915
2019-03-31 $433
2018-12-31 $-1,536
2018-09-30 $66
2018-06-30 $648
2018-03-31 $556
2017-12-31 $-11,336
2017-09-30 $727
2017-06-30 $739
2017-03-31 $821
2016-12-31 $14
2016-09-30 $249
2016-06-30 $347
2016-03-31 $513
2015-12-31 $-188
2015-09-30 $567
2015-06-30 $905
2015-03-31 $706
2014-12-31 $545
2014-09-30 $911
2014-06-30 $1,082
2014-03-31 $582
2013-12-31 $430
2013-09-30 $985
2013-06-30 $1,782
2013-03-31 $1,109
2012-12-31 $513
2012-09-30 $-183
2012-06-30 $1,180
2012-03-31 $711
2011-12-31 $434
2011-09-30 $1,216
2011-06-30 $1,077
2011-03-31 $894
2010-12-31 $-2,012
2010-09-30 $558
2010-06-30 $1,472
2010-03-31 $1,135
2009-12-31 $-807
2009-09-30 $1,092
2009-06-30 $786
2009-03-31 $1,074
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $148.702B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $790.248B 81.85
Novo Nordisk (NVO) Denmark $489.545B 35.30
Johnson & Johnson (JNJ) United States $373.278B 15.14
AbbVie (ABBV) United States $308.242B 16.23
Merck (MRK) United States $254.810B 16.93
Novartis AG (NVS) Switzerland $215.989B 14.36
AstraZeneca (AZN) United Kingdom $200.887B 17.90
Sanofi (SNY) $128.465B 11.64
Innoviva (INVA) United States $1.259B 10.48